Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Determine the Safety and Efficacy of Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)
NCT05571059 is registered in ClinicalTrials.gov with Cumberland Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Determine the Safety and Efficacy of Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- Lead sponsor
- Cumberland Pharmaceuticals
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- January 31, 2024
- Completion date
- January 31, 2028
- Enrollment
- 128 (estimated)
- Sites
- 20
Conditions
As the registry lists them; a condition with its own page is linked.